SARS-CoV-2

[BMC Medicine] After the first vaccination, the prevalence of IgG directed against the SARS-CoV-2 S-protein and its receptor binding domain varied from 55–95% to 100%, depending on the vaccine regimen and the SARS-CoV-2 antigen used.

[Nature Communications] Investigators used multi-omics single-cell analysis to probe the dynamic immune responses in hospitalized patients with stable or progressive course of COVID-19, explore V(D)J repertoires, and assess the cellular effects of tocilizumab.

[Molecular Imaging and Biology] A severe pulmonary ventilation-perfusion mismatch usually triggers moderate to severe COVID-19 cases. Imaging can aid the physician in assessing severity of COVID-19.

[Communications Biology] Researchers presented a standardized primary alveolar cell culture method for establishing a human alveolar epithelium model that could recapitulate viral infection and cellular plasticity.

[Scientific Reports] Scientists examined the expression of ACE2 in normal hearts and hearts from patients with terminal heart failure.

[Xilio Therapeutics, Inc.] Xilio Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment.